{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-029401","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.054196+00:00","generated_at":"2026-05-24T03:14:06.292702+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia's YUTREPIA NDA resubmission accepted; PDUFA date May 24, 2025","bullets":["FDA accepted Liquidia's NDA resubmission for YUTREPIA (treprostinil) inhalation powder.","Resubmission is a complete, Class 1 response to the August 16, 2024 action letter.","FDA granted tentative approval for PAH and PH-ILD; final approval decision by May 24, 2025.","Company preparing for launch of YUTREPIA pending final FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-029401","json":"https://secwatch.observer/filing/0001104659-25-029401.json","markdown":"https://secwatch.observer/filing/0001104659-25-029401.md","text":"https://secwatch.observer/filing/0001104659-25-029401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465925029401/0001104659-25-029401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465925029401/tm2510788-1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:14:06.292702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}